ASTELLAS PHARMA

🇯🇵Japan
Ownership
-
Established
2005-01-01
Employees
-
Market Cap
$22.5B
Website
https://www.astellas.com/
Clinical Trials
Related News

Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

First Posted Date
2015-10-07
Last Posted Date
2015-10-07
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
316
Registration Number
NCT02570035
Locations
🇯🇵

Site JP81007, Chiba, Japan

🇯🇵

Site JP81001, Hokkaido, Japan

🇯🇵

Site JP81025, Hyogo, Japan

and more 25 locations

Bioequivalence Evaluation of a New and Current Tablet of ASP015K

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: peficitinib
First Posted Date
2015-08-24
Last Posted Date
2024-10-16
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
40
Registration Number
NCT02531191

A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules

Phase 1
Completed
Conditions
Urine Phosphorus Excretion
Healthy
Interventions
Drug: ASP1585
First Posted Date
2015-08-24
Last Posted Date
2015-08-24
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
60
Registration Number
NCT02531204

Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

Phase 2
Completed
Conditions
Type 1 Diabetes Mellitus
Interventions
Drug: Placebo
Drug: ASP1941
First Posted Date
2015-08-20
Last Posted Date
2024-11-11
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
43
Registration Number
NCT02529449
Locations
🇯🇵

Site JP00010, Osaka, Japan

🇯🇵

Site JP00002, Fukuoka, Japan

🇯🇵

Site JP00008, Kanagawa, Japan

and more 8 locations

Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan

First Posted Date
2015-07-29
Last Posted Date
2024-11-05
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
24
Registration Number
NCT02510274
Locations
🇯🇵

Site: 4, Aichi, Japan

🇯🇵

Site: 3, Shizuoka, Japan

🇯🇵

Site: 1, Ibaraki, Japan

and more 2 locations

A Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Subjects

First Posted Date
2015-07-17
Last Posted Date
2015-07-17
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
124
Registration Number
NCT02500953

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

First Posted Date
2015-07-17
Last Posted Date
2024-11-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
31
Registration Number
NCT02500927
Locations
🇯🇵

Site: 1, Miyagi, Japan

🇯🇵

Site: 9, Hiroshima, Japan

🇯🇵

Site: 8, Hyogo, Japan

and more 8 locations

Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

Completed
Conditions
Type 2 Diabetes
Interventions
Drug: ipragliflozin
First Posted Date
2015-06-24
Last Posted Date
2024-10-22
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
11412
Registration Number
NCT02479399

A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy

Phase 1
Completed
Conditions
Cedar Pollinosis
Interventions
Drug: ASP4070
Drug: Placebo
First Posted Date
2015-06-11
Last Posted Date
2024-10-31
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
66
Registration Number
NCT02469688

A Study to Demonstrate Safety and Efficacy of Advagraf in Patients Undergoing Kidney or Liver Transplantation in India

Phase 4
Completed
Conditions
Liver Transplantation
Kidney Transplantation
Interventions
Drug: Advagraf
First Posted Date
2015-05-01
Last Posted Date
2015-05-01
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
92
Registration Number
NCT02432053
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy